Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Gastrointestinal Cancer
-
-
Alliance Announces FDA Approval of Atezolizumab Based on Results from the Phase III ATOMIC Trial for Patients with Stage III dMMR Colon Cancer
The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has approved the immunotherapy drug atezolizumab (Tecentriq®) in combination with fluoropyrimidine and oxaliplatin chemotherapy, for the adjuvant treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The approval is based on…
-
Sharing News from the Alliance: September Media Mentions
The media relations efforts from Alliance staff and researchers are designed to alert the public about the vital work happening across our network. When we share stories about clinical trial results, scientific milestones, or investigator achievements, we are showcasing the real-world progress you help make possible. See where the Alliance was mentioned September 2026 in…
-
Sharing News from the Alliance: August Media Mentions
Our media relations efforts are designed to inform the public about the vital work taking place across our clinical trials network. By sharing stories about clinical trial results, scientific milestones, and investigator achievements, we highlight the real-world progress made possible through the collective efforts of researchers, trial participants, and the broader cancer community. More than…
-
Sharing News from the Alliance in the Media: July Media Mentions
The media relations efforts from Alliance staff and researchers are designed to alert the public about the vital work happening across our network. When we share stories about clinical trial results, scientific milestones, or investigator achievements, we are showcasing the real-world progress you help make possible. More than just news mentions, these media stories serve…
-
Amplifying Our Shared Mission in the Media: June Media Mentions
At the Alliance for Clinical Trials in Oncology, our media relations efforts are designed to alert the public about the vital work happening across our network. When we share stories about groundbreaking clinical trials, scientific milestones, or investigator achievements, we are showcasing the real-world progress you help make possible. These media features serve a crucial…
-
Highlighting the Impact of the Alliance Research
At the Alliance for Clinical Trials in Oncology, we love sharing stories that show what’s happening in cancer research right now. Whether it’s a new clinical trial, a scientific breakthrough, or the work of one of our dedicated investigators, we want people to see the progress being made, and the real humans behind it. These…
-
Alliance Announces FDA Acceptance of Supplemental Biologics License Application Supported by Results from the Phase III ATOMIC Trial for Patients with Stage III dMMR Colon Cancer
The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech’s supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq®) for the treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The application is supported by…
-
Alliance Research at ASCO 2026
The Alliance for Clinical Trials in Oncology and Alliance Foundation Trials will present a diverse portfolio of research at the 2026 ASCO Annual Meeting, taking place May 29-June 2 in Chicago, Illinois, spanning breast, gastrointestinal, genitourinary, thoracic, neuro-oncology, health outcomes, and data science. Collectively, these studies reflect the continued leadership of the Alliance in practice-changing clinical trials, translational biomarker…